We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Coronavirus (COVID-19) Vaccine Approved for Clinical Trials in China

CanSino Biologics Inc. (Hong Kong, China), a biopharmaceutical company focusing on vaccine R&D and commercialization, has received approval for its recombinant novel coronavirus vaccine (Adenovirus Type 5 Vector) candidate (Ad5-nCoV), co-developed with the Beijing Institute of Biotechnology (BIB), for beginning Phase 1 clinical trial. It is currently the first novel coronavirus vaccine for COVID-19 to make it to this stage in China.

CanSinoBIO possesses four integrated platform technologies, including adenovirus-based vectors, conjugation, protein design and recombination and formulation. It currently has a robust pipeline of 16 vaccines covering 13 diseases, including a globally innovative Ebola virus vaccine approved for marketing in 2017, as well as the investigational Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector).

The recombinant novel coronavirus vaccine candidate is built upon CanSinoBIO’s adenovirus-based viral vector vaccine technology platform, which has also been successfully applied to develop the globally innovative vaccine against Ebola virus infection. Results from preclinical animal studies of Ad5-nCoV have shown that the vaccine candidate can induce strong immune response in animal models. The preclinical animal safety studies also demonstrated a good safety profile.

“Thanks to our collaborators and our diligent team, who worked almost around clock since late January to develop this vaccine candidate with sound scientific data to support IND filing,” said Xuefeng Yu, Chairman and CEO of CanSinoBIO, “Having committed to provide unconditional support to fight against the global epidemic, CanSinoBIO is determined to launch our vaccine product candidate as soon as possible with no compromise on quality and safety.”